You are here

  • Home
  • Archive
  • Volume 12, Issue 9
  • Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment
  1. P Ngo1 and
  2. R Bycroft2
  1. 1 Division of Hematology-Oncology, University of Louisville School of Medicine, Louisville, Kentucky, USA
  2. 2 Department of Pharmacy, University of Louisville, Louisville, Kentucky, USA
  1. Correspondence to Dr P Ngo, phuong.ngo{at}louisville.edu

Abstract

Inhibitors of BRAF, a gene coding a protein called B-raf, with or without inhibitors of MEK (MAPK/extracellular signal-regulated kinase) are often used as palliative treatment in BRAF-mutated metastatic melanoma. Recent data show improved progression-free survival with encorafenib with binimetinib, a newer BRAF/MEK inhibitor combination, compared with older agents, but there have been no reports of this treatment in the setting of renal and liver failure. We report a patient with disease-induced transaminitis and renal failure requiring dialysis who was successfully treated with encorafenib and binimetinib. His transaminitis improved and he was able to stop dialysis without any significant adverse effects during treatment, suggesting encorafenib with binimetinib may be used safely and effectively even in patients with end organ damage.

  • chemotherapy
  • skin cancer
  • pharmacology and therapeutics

https://doi.org/10.1136/bcr-2019-230974

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors PN wrote the manuscript with the exception of the treatment section and part of the follow-up section. She also cared for the patient during hospitalisation. RB wrote the treatment section and part of the follow-up section. He also played a key role in treating the patient and consented him for this manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.